D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment
Vanda Pharmaceuticals Inc. recently made a significant move by filing a new drug application for Tradipitant. The application, targeted at addressing motion sickness, was publicized through a social ...
Hosted on MSN29d
Vanda asserts FDA review of tradipitant was flawed
Vanda (NASDAQ:VNDA) had sought to have tradipitant approved for the treatment of patients with gastroparesis.The agency declined to approve the drug for the indication in September, issuing the ...
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...
FierceBiotech28d
After rejection, Vanda CEO pens searing letter to FDA commissioner about ‘disturbing pattern of conduct’
The biotech had requested approval for its NK-1R antagonist tradipitant in gastroparesis, with Polymeropoulos claiming at the time that the complete response letter (CRL) generally disregarded the ...
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Benzinga.com21d
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...
Vanda Pharmaceuticals: Buy Rating Affirmed Amidst Pipeline Progress and Strategic Expansion
Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda (VNDA – Research Report) and keeping the price target at ...
Vanda et Anaptys Bio concluent un accord mondial pour développer et commercialiser l'imsidolimab
AnaptysBio Inc : * VANDA PHARMACEUTICALS ET ANAPTYS ANNONCENT UN ACCORD DE LICENCE MONDIALE EXCLUSIVE POUR LE DÉVELOPPEMENT ...
Seeking Alpha29d
Vanda asserts FDA review of tradipitant was flawed
Vanda Pharmaceuticals (NASDAQ:VNDA) has sent a letter to FDA Commissioner Robert Califf asserting that the review of the New Drug Application for its drug tradipitant was flawed and that the ...
Morningstar10d
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...